Development of a serum miRNA panel for detection of early stage non-small cell lung cancer

doi:10.1073/pnas.2006212117

	Development of a serum miRNA panel for detection of early stage non-small cell lung cancer
	Ying, Lisha 9,10; Du, Lingbin 10,11; Zou, Ruiyang 12; Shi, Lei 10,14; Zhang, Nan 9,10; Jin, Jiaoyue 10,13; Xu, Chenyang 10; Zhang, Fanrong 10,15; Zhu, Chen 10,11; Wu, Junzhou 9,10
刊名	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
	2020-10-06
卷号	117
关键词	blood biomarker microRNA early detection
ISSN号	0027-8424
DOI	10.1073/pnas.2006212117
通讯作者	Su, Dan(sudan@zjcc.org.cn)
英文摘要	Minimally invasive testing for early detection of lung cancer to improve patient survival is a major unmet clinical need. This study aimed to develop and validate a serum multi-microRNA (multimiR) panel as a minimally invasive test for early detection of nonsmall cell lung cancer (NSCLC) regardless of smoking status, gender, and ethnicity. Our study included 744 NSCLC cases and 944 matched controls, including smokers and nonsmokers, male and female, with Asian and Caucasian subjects. Using RT-qPCR and a tightly controlled workflow, we quantified the absolute expression of 520 circulating microRNAs (miRNAs) in a Chinese cohort of 180 early stage NSCLC cases and 216 healthy controls (male smokers). Candidate biomarkers were verified in two case-control cohorts of 432 Chinese and 218 Caucasians, respectively (including females and nonsmokers). A multimiR panel for NSCLC detection was developed using a twofold cross-validation and validated in three additional Asian cohorts comprising 642 subjects. We discovered 35 candidate miRNA biomarkers, verified 22 of them, and developed a five-miR panel that detected NSCLC with area under curve (AUC) of 0.936-0.984 in the discovery and verification cohorts. The panel was validated in three independent cohorts with AUCs of 0.973, 0.916, and 0.917. The sensitivity of five-miR test was 81.3% for all stages, 82.9% for stages I and II, and 83.0% for stage I NSCLC, when the specificity is at 90.7%. We developed a minimally invasive five-miR serum test for detecting early stage NSCLC and validated its performance in multiple patient cohorts independent of smoking status, gender, and ethnicity.
资助项目	Major Science and Technology Project of Zhejiang Province of China[2014C03029] ; Major Science and Technology Project of Zhejiang Province of China[2020C03023] ; Public Welfare Technology Foundation of Zhejiang Province of China[2017C34001] ; National Natural Science Foundation of China[81972917] ; Major Science and Technology Project of Medical and Health of Zhejiang Province of China[WKJ-ZJ-1902] ; Zhejiang high-level innovative talent program ; 1022 programof Zhejiang Cancer Hospital
WOS关键词	FALSE DISCOVERY RATE ; MICRORNA ; SIGNATURE ; IDENTIFICATION ; STATISTICS ; EXPRESSION ; DIAGNOSIS ; MODEL ; TIME
WOS研究方向	Science & Technology - Other Topics
语种	英语
出版者	NATL ACAD SCIENCES
WOS记录号	WOS:000579045200009
资助机构	Major Science and Technology Project of Zhejiang Province of China ; Public Welfare Technology Foundation of Zhejiang Province of China ; National Natural Science Foundation of China ; Major Science and Technology Project of Medical and Health of Zhejiang Province of China ; Zhejiang high-level innovative talent program ; 1022 programof Zhejiang Cancer Hospital
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104627]
专题	中国科学院合肥物质科学研究院
通讯作者	Su, Dan
作者单位	1.Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Surg, Singapore 119077, Singapore 2.Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Biol Resource Ctr, Linhai 317000, Zhejiang, Peoples R China 3.Wenzhou Med Univ, Taizhou Hosp Zhejiang Prov, Dept Cardiothorac Surg, Linhai 317000, Zhejiang, Peoples R China 4.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Human Tissue Bank, Hangzhou 310022, Zhejiang, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg, Hangzhou 310022, Zhejiang, Peoples R China 6.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Clin Lab, Hangzhou 310022, Zhejiang, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Chemotherapy, Hangzhou 310022, Zhejiang, Peoples R China 8.Univ Hawaii, Canc Ctr, Honolulu, HI 96813 USA 9.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Canc Res Inst, Hangzhou 310022, Zhejiang, Peoples R China 10.Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Ying, Lisha,Du, Lingbin,Zou, Ruiyang,et al. Development of a serum miRNA panel for detection of early stage non-small cell lung cancer[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,2020,117.
APA	Ying, Lisha.,Du, Lingbin.,Zou, Ruiyang.,Shi, Lei.,Zhang, Nan.,...&Su, Dan.(2020).Development of a serum miRNA panel for detection of early stage non-small cell lung cancer.PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,117.
MLA	Ying, Lisha,et al."Development of a serum miRNA panel for detection of early stage non-small cell lung cancer".PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 117(2020).